Instruction for self-administration is mentioned in the Package Leaflet. The needle protection system of the Arixtra pre-filled syringes have been designed with a. Please read this leaflet carefully before you start using Arixtra. This leaflet answers some common . package insert in each Arixtra carton. Mylan manufactures ARIXTRA®* (fondaparinux sodium) Injection, Solution ( Arixtra) in strengths of 25 mg05 mL 5 mgmL5 Category: Human Prescription Drug.
|Published (Last):||15 July 2017|
|PDF File Size:||16.86 Mb|
|ePub File Size:||14.46 Mb|
|Price:||Free* [*Free Regsitration Required]|
For example, it is known that unfractionated heparin use, especially beyond 4 days of treatment, is known to have a greater risk for causing HIT when compared to Arrixtra dalteparin, enoxaparin, and tinzaparin.
While low-molecular weight heparins LMWH can also cause HIT, the incidence is much lower and appears to be related, in part, to the molecular weight.
However, the longer the use especially if used at therapeutic doses the greater the incidence of HIT. The reference to the chain is related to the part of the heparin molecule attached to the pentasaccharide sequence pakcage is used in binding to antithrombin when exerting its antithrombotic effect. It is also worth noting that some patients with HIT have been shown to have platelet recovery with fondaparinux administration.
An evaluation of the molecular weights among the heparin related medications reveals that UFH’s molecular weight ranges from 3, to 30, daltons whereas, the LMWH range from pakcage, to 10, daltons. Please enter text to search. Treatment and Prevention of Arixta Induced Thrombocytopenia: However, they are also known to cause clinically relevant side effects, or adverse drug events, such as bleeding including hemorrhagic stroke, gastrointestinal bleeding, osteoporosis long-term usepriapism, and hyperkalemia from inhibition of aldosterone synthesis.
While the use of heparin based anticoagulants have improved patient packaeg outcomes in patients with thrombosis related medical conditions, they paradoxically are also known to put some patients at risk for developing the life threatening thrombosis called heparin induced thrombocytopenia HIT.
The incidence of HIT is greatest in unfractionated heparin use beyond 4 days at therapeutic doses.
Explanation The use of anticoagulants, such as unfractionated heparin UFH and low-molecular weight heparin LMWH have significantly improved patient oriented outcomes for medical conditions related to thrombotic events. There are number of risk factors associated with increasing the chance for a patient to develop HIT, one of which is the type of anticoagulant used.
Fondaparinux Arixtra is an anticoagulant that shares the same pentasaccharide sequence as UFH and LMWH for the binding to antithrombin, however it has no extra chain and thus, is not considered a heparin product.
Linkins LA et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: Research Triangle Park, NC.
About Us Disclaimer Contact Us. The use of anticoagulants, such as unfractionated heparin UFH and low-molecular weight heparin LMWH have significantly improved patient oriented outcomes for medical conditions arxitra to thrombotic events.
As noted above, the length of the chain which influences the molecular weight contributes, in part, to heparin’s ability to bind to PF4 that triggers the immune mediated response seen in HIT. Treatment and prevention of heparin-induced thrombocytopenia: The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria.